Get the Stockscreener App
36.43
2.70%
0.9094
Newamsterdam Pharma Company Nv stock is traded at $36.43, with a volume of 609.52K.
It is up +2.70% in the last 24 hours and down -0.14% over the past month.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
See More
Previous Close:
$35.52
Open:
$36.6
24h Volume:
609.52K
Relative Volume:
0.55
Market Cap:
$4.12B
Revenue:
$14.09M
Net Income/Loss:
$-176.94M
P/E Ratio:
-16.94
EPS:
-2.15
Net Cash Flow:
$-141.24M
1W Performance:
-11.99%
1M Performance:
-0.14%
6M Performance:
+88.14%
1Y Performance:
+99.67%
1-Day Range:
$34.99
$36.60
1-Week Range:
$34.52
$41.80
52-Week Range:
$14.06
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company Nv
Sector
Industry
Phone
35 206 2971
Address
GOOIMEER 2-35, NARRDEN
Compare NAMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
36.34 | 4.03B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.44 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.02 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.95 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
922.40 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.06 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Resumed | H.C. Wainwright | Buy |
| Aug-25-25 | Initiated | Wells Fargo | Overweight |
| Jul-17-25 | Initiated | Goldman | Neutral |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jun-10-25 | Initiated | Stifel | Buy |
| Jun-04-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| May-15-24 | Initiated | TD Cowen | Buy |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-18-24 | Initiated | Guggenheim | Buy |
| Jan-16-24 | Initiated | Piper Sandler | Overweight |
| Oct-30-23 | Initiated | RBC Capital Mkts | Outperform |
View All
Newamsterdam Pharma Company Nv Stock (NAMS) Latest News
NAMS: PREVAIL CVOT remains on track for 2026, with regulatory and commercial momentum building - TradingView
Is NewAmsterdam Pharma Company N.V. (KH6) stock attractive post correction2025 Stock Rankings & Real-Time Chart Breakout Alerts - Newser
How NewAmsterdam Pharma Company N.V. (KH6) stock trades after earningsWeekly Trade Analysis & Consistent Profit Trade Alerts - Newser
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock gain from lower inflationAnalyst Upgrade & Weekly High Conviction Ideas - Newser
Transcript : NewAmsterdam Pharma Company N.V. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 03 - MarketScreener
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock see PE expansion2025 Momentum Check & Fast Moving Stock Trade Plans - Newser
Is NewAmsterdam Pharma Company N.V. (KH6) stock a defensive play amid uncertaintyEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
Will NewAmsterdam Pharma Company N.V. stock benefit from commodity pricesGap Down & Smart Money Movement Alerts - Newser
Will NewAmsterdam Pharma Company N.V. (KH6) stock announce special dividendWeekly Earnings Recap & Technical Entry and Exit Alerts - Newser
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock a dividend growth opportunity2025 Risk Factors & AI Forecasted Entry and Exit Points - Newser
Why NewAmsterdam Pharma Company N.V. (KH6) stock signals breakout potential2025 Stock Rankings & Low Drawdown Momentum Ideas - Newser
(NAMS) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock outperform in 2025 bull marketPortfolio Gains Report & Technical Buy Zone Confirmation - BỘ NỘI VỤ
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December - Sahm
NewAmsterdam Pharma stock hits all-time high at 41.56 USD - Investing.com India
NewAmsterdam Pharma stock hits all-time high at 41.56 USD By Investing.com - Investing.com Australia
NewAmsterdam (Nasdaq: NAMS) to host investor fireside chats at Evercore, Citi, Piper - Stock Titan
Discipline and Rules-Based Execution in NAMSW Response - news.stocktradersdaily.com
What drives NewAmsterdam Pharma Company NV KH6 stock priceDebt-to-Equity Ratio Analysis & Get Ahead with Our Profit-Packed Picks - earlytimes.in
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock a top pick in earnings seasonSwing Trade & Safe Investment Capital Preservation Plans - newser.com
Can a trend reversal in NewAmsterdam Pharma Company N.V. Equity Warrant lead to recovery - newser.com
Technical analysis overview for NewAmsterdam Pharma Company N.V. Equity Warrant stockMarket Movers & Risk Controlled Stock Alerts - newser.com
Is NewAmsterdam Pharma Company N.V. stock a good choice for value investorsQuarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Will NewAmsterdam Pharma Company N.V. stock maintain dividend yield - newser.com
Is NewAmsterdam Pharma Company N.V. (KH6) stock a fit for income portfoliosOil Prices & Long-Term Growth Stock Strategies - newser.com
How NewAmsterdam Pharma Company N.V. stock performs in high volatility marketsPortfolio Gains Report & Safe Entry Zone Identification - newser.com
What does recent volatility data suggest for NewAmsterdam Pharma Company N.V. Equity WarrantPortfolio Growth Summary & Technical Buy Zone Confirmation - newser.com
How NewAmsterdam Pharma Company N.V. (KH6) stock compares with tech leaders2025 Momentum Check & Risk Adjusted Swing Trade Ideas - newser.com
Visual analytics tools that track NewAmsterdam Pharma Company N.V. Equity Warrant performanceIndex Update & Weekly High Momentum Picks - newser.com
How NewAmsterdam Pharma Company N.V. Equity Warrant stock performs in stagflation2025 Biggest Moves & AI Forecast for Swing Trade Picks - newser.com
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock recover faster than marketJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
(NAMS) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock withstand economic slowdownJuly 2025 Action & Precise Swing Trade Entry Alerts - newser.com
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock maintain momentum in 2025 - newser.com
Published on: 2025-11-16 17:37:14 - newser.com
Advanced analytics toolkit walkthrough for NewAmsterdam Pharma Company N.V. Equity WarrantMarket Volume Report & Low Drawdown Momentum Trade Ideas - newser.com
NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating (NASDAQ:NAMS) - Seeking Alpha
Why NewAmsterdam Pharma Company N.V. stock is seen as undervaluedDollar Strength & AI Based Buy and Sell Signals - newser.com
Can NewAmsterdam Pharma Company N.V. (KH6) stock surprise markets with earningsPortfolio Risk Summary & Long-Term Safe Investment Plans - newser.com
Using data models to predict NewAmsterdam Pharma Company N.V. Equity Warrant stock movement2025 Technical Overview & Accurate Intraday Trade Tips - newser.com
Tools to assess NewAmsterdam Pharma Company N.V.’s risk profile2025 Dividend Review & Technical Confirmation Trade Alerts - newser.com
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock trading at a premium valuationJuly 2025 Recap & Technical Pattern Based Buy Signals - newser.com
Newamsterdam Pharma Company Nv Stock (NAMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.13%
1.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):